Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Arsenic Trioxide in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2004-06-24

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003630

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2004-06-18

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00005616

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: MUC-2-KLH vaccine
Biological: QS21

First Posted Date: 2004-06-18

Last Posted Date: 2013-01-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT00004929

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-16

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003242

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Prostate Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-06-11

Last Posted Date: 2016-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00085566

Locations: 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: cisplatin
Drug: safingol

First Posted Date: 2004-06-11

Last Posted Date: 2013-03-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT00084812

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-11

Last Posted Date: 2013-01-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00084786

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2

Withdrawn

Conditions: Melanoma (Skin)

First Posted Date: 2004-06-11

Last Posted Date: 2012-12-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00085579

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: fluorouracil
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2004-06-11

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT00084773

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Biological Therapy in Treating Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-06-10

Last Posted Date: 2013-06-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT00002637

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy